Literature DB >> 6252835

Carbenicillin plus cefazolin with or without mecillinam as an early treatment of bacteremia caused by gram-negative organisms: randomized double-blind study.

J Klastersky, L Coppens, F Meunier-Carpentier, A P Menday.   

Abstract

Mecillinam or a placebo was added to a combination of cefazolin and carbenicillin as an early therapy of septicemia caused by gram-negative organisms in patients with serious underlying diseases, none of whom was neutropenic, however. Patients in whom infection was caused by pathogens against which mecillinam and cefazolin or mecillinam and carbenicillin were synergistic might have responded more often than patients treated with nonsynergistic combinations. However, overall results did not show any benefit from combining mecillinam with cefazolin and carbenicillin. This study suggests that in nonneutropenic patients with septicemia caused by gram-negative organisms, there is no need to intensify antimicrobial therapy beyond a certain point of efficacy. The measurement of the bactericidal activity in the serum of treated patients might serve as guide for adequate therapy.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6252835      PMCID: PMC284019          DOI: 10.1128/AAC.18.3.437

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Mecillinam (FL 1060), a 6beta-amidinopenicillanic acid derivative: in vitro evaluation.

Authors:  L Tybring
Journal:  Antimicrob Agents Chemother       Date:  1975-09       Impact factor: 5.191

2.  Mecillinam, a novel penicillanic acid derivative with unusual activity against gram-negative bacteria.

Authors:  H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1976-05       Impact factor: 5.191

3.  Clinical significance of in vitro synergism between antibiotics in gram-negative infections.

Authors:  J Klastersky; R Cappel; D Daneau
Journal:  Antimicrob Agents Chemother       Date:  1972-12       Impact factor: 5.191

4.  Antibacterial activity in serum and urine as a therapeutic guide in bacterial infections.

Authors:  J Klastersky; D Daneau; G Swings; D Weerts
Journal:  J Infect Dis       Date:  1974-02       Impact factor: 5.226

5.  Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.

Authors:  J Klastersky; C Hensgens; L Debusscher
Journal:  Antimicrob Agents Chemother       Date:  1975-05       Impact factor: 5.191

6.  Gram-negative infections in cancer. Study of empiric therapy comparing carbenicillin-cephalothin with and without gentamicin.

Authors:  J Klastersky; A Henri; C Hensgens; D Daneau
Journal:  JAMA       Date:  1974-01-07       Impact factor: 56.272

7.  Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia.

Authors:  S Schimpff; W Satterlee; V M Young; A Serpick
Journal:  N Engl J Med       Date:  1971-05-13       Impact factor: 91.245

8.  In vivo synergy between 6 beta-amidinopenicillanic acid derivatives and other antibiotics.

Authors:  E Grunberg; R Cleeland; G Beskid; W F DeLorenzo
Journal:  Antimicrob Agents Chemother       Date:  1976-04       Impact factor: 5.191

9.  Significance of antimicrobial synergism for the outcome of gram negative sepsis.

Authors:  J Klastersky; F Meunier-Carpentier; J M Prevost
Journal:  Am J Med Sci       Date:  1977 Mar-Apr       Impact factor: 2.378

10.  Ticarcillin in combination with cephalothin or gentamicin as empiric antibiotic therapy in granulocytopenic cancer patients.

Authors:  S C Schimpff; S Landesman; D M Hahn; H C Standiford; C L Fortner; V M Young; P H Wiernik
Journal:  Antimicrob Agents Chemother       Date:  1976-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.